Sir, Group B Streptococcus (Streptococcus agalactiae; GBS) is the main cause of neonatal sepsis and meningitis, as well as invasive infections in adults, particularly in the elderly and individuals with underlying medical conditions. 1 All clinical isolates of GBS are considered uniformly susceptible to b-lactams; therefore, b-lactams, in particular penicillins, are utilized as first-line agents for the prevention and treatment of GBS infections. 1, 2 In 2008, we characterized clinical isolates of GBS with reduced penicillin susceptibility (PRGBS), with amino acid substitutions in PBP2X, in Japan.
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3,4 After our initial report, 3 similar clinical isolates of PRGBS with amino acid substitutions in PBP2X were reported in North America. [5] [6] [7] To elucidate the emergence mechanisms of PRGBS, we tested the hypothesis that clinical PRGBS isolates have emerged from clinical isolates that possess survival advantage under specific antibiotic selective pressure. Although penicillin G represents the first-line agent for the prevention and treatment of GBS infections in many countries, ampicillin is widely prescribed as the first-line agent for the prevention and treatment of GBS infections in Japan owing to the low availability of penicillin G in this country. Therefore, in the present study, we used 15 genetically characterized PRGBS 3, 8 and 18 penicillin-susceptible GBS (PSGBS) to examine the difference in the killing effects of ampicillin against PRGBS and PSGBS.
The MIC of ampicillin was determined by the microdilution method, in accordance with the CLSI guidelines. 9 Clinical isolates were cultured until OD 530 " 0.6, indicating the exponential phase, and inoculated at a concentration of 5.0 % 10 5 cfu/mL in Todd Hewitt broth. Then, each concentration of ampicillin (final 1%, 2%, 4% and 10% MIC) was added and cultured for 0, 2 and 4 h. Next, live cell counts for each timepoint were determined by inoculating on sheep blood agar plates: following a 2 h exposure to ampicillin, 0.5% of the inoculum survived. These clinical isolates were defined as harbouring the 'slowly-killed-by-ampicillin' phenotype (SK phenotype). The v 2 test was performed using Prism 4 (GraphPad) and P 0.05 was considered to represent statistical significance.
For the MLST, chromosomal DNA was prepared using a Wizard genomic DNA purification kit (Promega) with mutanolysin and lysozyme. STs were determined using MLST databases for S. agalactiae (http://pubmlst.org/sagalactiae/), according to the method described previously. 10 Grouping of the STs was performed using eBURST V3 (http://eburst.mlst.net/).
The numbers of clinical isolates that were found to harbour the SK phenotype and the non-SK phenotype are shown in Table 1 . Among the 15 clinical PRGBS isolates, 10 were SK and 5 non-SK. However, 5 of the 18 PSGBS isolates were SK and 13 were non-SK. The difference was statistically significant (P " 0.0255). These data show that the rate of SK among the PRGBS isolates is statistically higher than among the PSGBS isolates.
The clinical isolates analysed in this investigation were divided into four subgroups: PRGBS/SK, PRGBS/non-SK, PSGBS/SK and PSGBS/non-SK. Their STs were determined by MLST analysis. Using eBURST: ST1, 387, 458, 676 and 755 were classified as belonging to the ST1 group; ST10 and 12 were classified as belonging to the ST10 group; and ST19 and 110 were classified as belonging to the ST19 group (Table S1 and Figure S1 , available as Supplementary data at JAC Online).
In the present study, a significant association between SK and reduced penicillin susceptibility (P " 0.0255) was identified. Among PSGBS, isolates with an SK phenotype were found, suggesting that some clinical isolates of GBS harbour the SK phenotype. However, a high proportion of PRGBS clinical isolates were found to harbour the SK phenotype, suggesting that certain PRGBS clinical isolates may have emerged from populations of PSGBS isolates that harbour the SK phenotype.
Some PRGBS clinical isolates exhibited reduced ampicillin susceptibility, suggesting that the elevated MICs of ampicillin may affect the SK phenotype. However, the distribution of ampicillin MICs (Table S1 ) and the average ampicillin MIC for isolates with an SK phenotype were 0.03-0.25 and 0.193 mg/L, respectively, whereas the corresponding values for isolates with a non-SK phenotype 
